Company ReShape Lifesciences OTC Markets
Equities
RSLS
US7611236032
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.09 USD | +23.84% | -.--% | -.--% |
05-15 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-15 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Minimally Invasive Medical Devices
100.0
%
| 11 | 100.0 % | 9 | 100.0 % | -22.79% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
82.2
%
| 9 | 82.1 % | 7 | 82.2 % | -22.71% |
Europe
11.0
%
| 1 | 11.1 % | 1 | 11.0 % | -23.64% |
Australia
6.1
%
| 1 | 6.1 % | 1 | 6.1 % | -23.55% |
Rest of World
0.7
%
| 0 | 0.6 % | 0 | 0.7 % | -11.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 20-01-31 |
Director of Finance/CFO | 63 | 21-06-14 | |
Dov Gal
CMP | Compliance Officer | - | - |
Al Diaz
COO | Chief Operating Officer | - | 21-08-30 |
Nick Ansari
PRN | Corporate Officer/Principal | 62 | 22-09-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 15-12-31 |
Dan Gladney
CHM | Chairman | 70 | 15-10-31 |
Director/Board Member | 70 | 21-06-14 | |
Paul Hickey
CEO | Chief Executive Officer | 59 | 20-01-31 |
Lori McDougal
BRD | Director/Board Member | 62 | 15-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 95,388 | 0 | 0 | 88.83 % |
Stock B | 1 | 23,457,090 | 20,838,013 ( 88.83 %) | 0 |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+4.18% | 211B | |
+8.00% | 185B | |
+31.86% | 158B | |
+33.21% | 113B | |
+2.28% | 64.32B | |
+21.14% | 55.66B | |
+0.11% | 48.41B | |
-6.76% | 37.82B | |
+0.78% | 35.57B |
- Stock Market
- Equities
- RSLS Stock
- RSLS Stock
- Company ReShape Lifesciences